Kolexia
Samalin Scalzi Emmanuelle Gastro-entérologie
Samalin Scalzi Emmanuelle
Gastro-entérologie
Icm Montpellier
Montpellier, France
193 Activités
5 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Adénocarcinome Tumeurs colorectales Carcinomes Métastase tumorale Tumeurs de l'estomac Carcinome épidermoïde Tumeurs de l'oesophage Tumeurs du pancréas Récidive tumorale locale

Collaborateurs

Voir plus
Ychou Marc
Ychou Marc
Icm Montpellier, Montpellier, France
De La Fouchardiere Christelle
De La Fouchardiere Christelle
Centre Paoli-Calmettes, Marseille, France
Portales Fabienne
Portales Fabienne
Icm Montpellier, Montpellier, France
Mazard Thibault
Mazard Thibault
Icm Montpellier, Montpellier, France

Industries

Voir plus
Pierre Fabre
26 collaboration(s)
Dernière en 2023
Servier
25 collaboration(s)
Dernière en 2023
Roche
11 collaboration(s)
Dernière en 2021
MSD
10 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
SCARCE: A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma
Essai Clinique (Roche)   08 mars 2024
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Essai Clinique (Unicancer)   26 février 2024
Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   16 janvier 2024
OPALINE: AN OBSERVATIONAL REAL-WORLD STUDY OF THE SYSTEMIC TREATMENT OF WELL-DIFFERENTIATED, UNRESECTABLE OR METASTATIC, PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOURS (PNET): A STUDY OF MORBIDITY AND MORTALITY AT 2 YEARS
Essai Clinique (Pfizer)   09 novembre 2023
Pathogenic alterations in PIK3CA and KMT2C are frequent and independent prognostic factors in anal squamous cell carcinoma treated with salvage abdominoperineal resection.
International journal of cancer   31 octobre 2023
Treatment of gastric adenocarcinoma: A rapidly evolving landscape.
European journal of cancer (Oxford, England : 1990)   17 octobre 2023
REGIRI: A Randomised Phase 2 Trial Assessing REGorafenib Combined With IRInotecan as Second-line Treatment in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
Essai Clinique (Bayer)   13 octobre 2023
1520P Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
651P DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1555P Cell-free DNA analysis in patients with metastatic gastroesophageal adenocarcinoma: Preliminary results of the REGIRI - PRODIGE 58 ancillary study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023